AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03379805 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Near Infrared Fluorescence Imaging
Description: The functional state of lymphatics is investigated using near infrared fluorescence imaging, NIRF.
Study NCT03379805 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Non-contrast MRI
Description: The anatomy is described using non-contrast MRI.
Study NCT03379805 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Strain Gauge Plethysmography
Description: The capillary filtration rate is measured using plethysmography
Study NCT01193868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally
Study NCT01193868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01193868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01087073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Training
Description: Provider patient-centered communication training focuses on cultural competency and communication skills training to aid in shared decision-making and tailoring treatment recommendations to the patient's cultural preferences and readiness. Providers attend 4 1-hour monthly modules and one booster workshop 3 months post-class.
Study NCT01087073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality Improvement
Description: Participating clinics participate in quality improvement (QI) programs which aim to redesign clinic operations to improve care for diabetes patients. QI initiatives have included instituting group visits, patient medication cards, peer support groups, flow sheets, nurse case management, and patient registries. New initiatives include improving access and tracking of specialists visits, employing community health workers/patient navigators, coordinating care, and implementing other team-based care initiatives. Provider and clinical staff members from all six project clinics attend collaborative quarterly QI sessions with project staff to discuss improvements in QI efforts, share QI methods among clinic teams, and provide brief training sessions.
Study NCT01087073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Outreach
Description: The project collaborates with many community based organizations and resources to reach out to communities at high risk for diabetes on the South Side of Chicago and facilitate diabetes education, particularly in the area of nutrition and physical activity. We provide monthly health education events, nutrition tours, and frequently participate in community-based health fairs and health promotion events. We also work to promote nutrition through the Food Rx program, which utilizes a prescription to link patients at our clinics with nutrition resources on the South Side of Chicago through a coupon that gives discounts towards healthy purchases at participating stores, and have initiated a 10-week fitness program to promote physical activity among minority patients with diabetes.
Study NCT00772343 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: 0.5 mL, intramuscular on Days 0, 7, and 28
Study NCT00772343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoid vaccine
Description: 0.5 mL, intramuscular on Days 0, 7, and 28
Study NCT00772343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoid vaccine with adjuvant
Description: 0.5 mL, intramuscular on Days 0, 7, and 28
Study NCT03467191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: target BAC .08%
Study NCT04338542 — intervention group
Intervention type: GENETIC
Intervention: Tumor biobsies analysis
Description: Analysis on archived tumor biopsies
Study NCT02966665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate
Description: Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, passive leg movement test, exercise bouts, electromyography and exercise training regimen at baseline and following treatment with Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min), antioxidant cocktail (Vitamin C, Vitamin E, alpha-lipoic acid) ingestion, L-ascorbate injection, BH4 ingestion.
Study NCT03467191 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo beverage
Study NCT01717261 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single Pre-Operative Radiation Therapy
Description: Dose escalation: 3 patients will receive 15 Gy in a single fraction. The following 3 patients will receive 18 Gy. The final 4 patients will receive 20 Gy.
Study NCT02649998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Furosemide is the most commonly used medication for treatment of heart failure. It causes a direct vasodilator effect shortly after administration, followed by diuresis induction. However, furosemide also activates both the sympathetic and the renin angiotensin systems, causing a rise in peripheral resistance.
Study NCT02649998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: Isosorbide dinitrate is a vasodilator which is also well-known for treating acute decompensated heart failure. It induces acute venodilatation at low dose and arteries dilation when gradually increasing the dose. The effect peaks 5 min after administration.
Study NCT00428285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Argon Plasma Coagulation
Description: Argon Plasma Coagulation (APC) is a non-contact electrosurgical technique delivering a high-frequency electrical current through ionized argon gas i.e. the argon plasma. This current produces a zone of coagulation, desiccation, and devitalisation 2-3 mm deep. Patients will be offered up to 3 treatments if recurrence occur after the first two.
Study NCT00605228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOVIPREP
Description: 2L Drug
Study NCT00605228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COLOPEG
Description: 4L Drug
Study NCT02541994 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pachette3
Description: Central corneal thickness will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
Study NCT02541994 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lenstar-Think
Description: Axial length will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
Study NCT04224909 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Video Head Impulse Test
Description: Diagnosis of dysfunction of the semicircular canals using the vHIT
Study NCT04313309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Yoga Therapy
Description: Individualised intervention developed, consists of a six one to one sessions with patients, followed by home self practiced sessions. The intervention includes yoga movements, yoga breathing, relaxation techniques, reasoning, and other techniques designed to enhance awareness and acceptance of the psychological factors underlying the chronic pain problem.
Study NCT03266367 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil gelatinase-associated lipocalin (NAGL)
Description: Serum level of Neutrophil gelatinase-associated lipocalin (NAGL) using the enzyme linked immunosorbent assay kits (ELISA)
Study NCT02280109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Gel
Description: single dose of 1% tenofovir gel (equivalent to 40 mg in 4ml's of gel)
Study NCT02280109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Film
Description: single dose of 1.3% tenofovir film (equivalent to 40 mg)
Study NCT04631016 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI3506
Description: Dose 1
Study NCT04631016 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose 1
Study NCT00645736 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03442933 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 hours Road Cycling Time Trial
Description: The road itinerary is a mixed route profile of 90 km, an elevation gain of 900 m, with mixed sections, flat, uphill and down over roads with little traffic.
Study NCT03442933 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 hours Mountain Biking Time Trial
Description: The mountain itinerary, is a mixed route of 55 km, an elevation gain of 600 m, with sections of wide tracks and trails, flat, uphill and down, with a medium technical difficulty.
Study NCT00398086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered by intravenous infusion over 30 minutes.
Study NCT02454296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracervical Block with lidocaine
Description: Performance of paracervical block, using 18 mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate, prior to laminaria insertion
Study NCT02454296 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham paracervical block
Description: A capped needle will be placed on the cervix prior to laminaria insertion for purposes of blinding both the participant and research staff assessing outcomes
Study NCT04026308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safety Net App
Description: The Safety Net app is an electronic version of a safety plan and it is available for download in Apple's App Store. A preview of the app is available at: https://apps.apple.com/us/app/stanley-brown-safety-plan/id695122998. This app is owned by Two Penguins Studios, LLC. It was developed in partnership with the New York State Office of Mental Health. Unlike the paper version, the Safety Net app allows participants to email a copy of their safety plan to whomever they wish. It also allows patients to dial 911 or the National Suicide Prevention Lifeline from the app.
Study NCT05188911 — intervention group
Intervention type: DRUG
Intervention: Abiraterone
Description: Patients would be treated with 1000mg abiraterone qd.
Study NCT05188911 — intervention group
Intervention type: DRUG
Intervention: Prednisone
Description: Patients would be treated with 5mg prednisone bid.
Study NCT05188911 — intervention group
Intervention type: DRUG
Intervention: Androgen deprivation therapy
Description: Patients would get medical or surgical castration.
Study NCT00959764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Calcitonin Tablets
Description: Oral Calcitonin tablets along with matching placebo intranasal spray
Study NCT00959764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Calcitonin
Description: Intranasal Calcitonin Spray
Study NCT00959764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets and placebo intranasal spray
Description: Oral Placebo Tablets/Intranasal placebo spray
Study NCT00398086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel
Description: Administered by intravenous infusion over 30 minutes.
Study NCT02966665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123
Description: Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with endothelin-1 receptor antagonist BQ-123 (D-tryptamine-D-aspartic acid-L-proline-D-valine-L-leucine).
Study NCT01887613 — intervention group
Intervention type: DRUG
Intervention: Regnite
Description: oral
Study NCT00316706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)
Description: Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule
Study NCT00316706 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix™
Description: Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule.
Study NCT01420913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin 300mg a day
Study NCT01420913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 300mg a day
Study NCT03803358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training with non-invasive ventilation
Description: In the intervention group (exercise training with non-invasive ventilation) exercise NIV pressures will be optimally adjusted to each individual patient to decrease TcPCO2 values. An IPAP of at least 15 cmH20 will be used to provide sufficient pressure to relief patients breathing muscles. Nocturnal NIV will be continued.
Study NCT03803358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard exercise training without NIV
Description: In the control Group (standard exercise training without NIV ), patients will be execute cycle exercise without additional NIV (usual care). Nocturnal NIV will be continued.
Study NCT01393665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PENNEL capsule
Description: hard capsule DDB 25mg \& GO 50mg in cap .......... 1 capsule~1 or 2 capsule, T.I.D
Study NCT01393665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00656058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Singulair (Montelukast Sodium)
Description: Singulair (Montelukast Sodium):5-10 mg (weight based dosing) by mouth (PO) hour of sleep (HS)
Study NCT04305509 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT00564902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3R 3'R Zeaxanthin
Description: 8 mg per day during 12 months
Study NCT00564902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lutein
Description: 9 mg of Lutein during 12 months
Study NCT00564902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein and Zeaxanthin
Description: 8 mg of lutein and 8 mg of Zeaxanthin administered during 12 months
Study NCT03849053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mézières Therapy for Low back pain
Description: Spinal muscular global stretching
Study NCT03849053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mézières Therapy for Low back pain
Description: Spinal muscular global stretching
Study NCT04452357 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PLDR
Description: PLDR radiation will be delivered as 10 fractions of 20 cGy, initiated once every 3 minutes. Dose levels will be selected as follows:~Dose level 1: 56 Gy; Dose level 2: 66 Gy Drug: Gemcitabine
Study NCT03244709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Intravenous Tocilizumab followed by subcutaneousTocilizumab
Study NCT03332199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention
Description: The total program, consisting of three intervention sessions, was given over a period of 3 weeks. The one face-to-face session of an-hour's duration was provided within a week of the chemotherapy cycle following recruitment. Two booster sessions of 20-30 minutes were then conducted by phone at one-week intervals after the first intervention session.
Study NCT03742310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D is essential for healthy bones, and to control the amount of calcium in our blood.It is important at every stage of life, but especially for rapidly growing infants and teenagers and for pregnant and breastfeeding women.
Study NCT03028415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMPLEX
Description: A bone graft substitute
Study NCT03028415 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous Bone Graft (ABG)
Description: Control material administered by surgical implant
Study NCT01263418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Intravenous; Dosage: 1000mg; Frequency: one time per week; Duration: 8 weeks
Study NCT04989556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Participate in interview
Study NCT04989556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in interview
Study NCT04989556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palliative Therapy
Description: Receive standard symptom management by palliative care team
Study NCT04989556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Therapy
Description: Receive standard symptom management by palliative care team
Study NCT04989556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Therapy
Description: Receive provider initiated remote contact
Study NCT04989556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04989556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03987529 — intervention group
Intervention type: OTHER
Intervention: sevoflurane
Description: volatile anesthetic
Study NCT03987529 — intervention group
Intervention type: OTHER
Intervention: propofol
Description: intravenous anesthetic
Study NCT02015871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Study NCT04989556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT04361136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application
Study NCT04361136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delgocitinib cream vehicle
Description: The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Study NCT02308163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peficitinib
Description: oral
Study NCT02308163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT02308163 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: subcutaneous injection
Study NCT03802630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg
Description: Solution for injection (intravitreal use)
Study NCT03802630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 2 mg
Description: Solution for injection (Intravitreal use)
Study NCT03802630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham injection
Description: Empty sterile syringe without a needle administered as a sham injection for masking purposes.~From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.
Study NCT03802630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham injection
Description: Empty sterile syringe without a needle administered as a sham injection for masking purposes.~From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.
Study NCT02565758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-085
Description: Administered as an intravenous infusion in 28-day dosing cycles.
Study NCT02438683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: high dose, single dose, oral administration
Study NCT02438683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: low dose, single dose, oral administration
Study NCT02438683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose, oral administration
Study NCT01058681 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: effect of metabolic variations on LH pulsatility
Description: Isocaloric diet: 1,5 times basal metabolism. Constitution:55% carbohydrates, 15% proteins and 30% fat.~Hypercaloric diet: addition of 30% fat and 3 g of fructose/kg of weight to isocaloric diet.~PO and IV glucose during clamps: PO administration of 90 mg/kg glucose at 90 minutes intervals during the clamp, and adjustment of the IV perfusion to keep euglycemia.
Study NCT02485639 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine Inactivated
Description: A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season. All participants received vaccine intramuscularly (IM) on Day 0.
Study NCT00712686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Tablets, Oral, 15-30 mg, once daily, 140 weeks